Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel and Trastuzumab Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer

Trial Profile

Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel and Trastuzumab Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Vorinostat (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 13 Jul 2015 Planned End Date changed from 1 Jan 2010 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top